Clinical trials: Depression NOS
Treatment Resistant Depressive Disorder
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).
- Trial name
- NCT05196971
- Testing
- HS-10345 84mg
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bipolar Disorder
Depressive Symptoms in Acute Manic Episode
Observational, non-interventional, transversal, multicenter, open label (No treatment is involved). The primary objective is to detect the prevalence of depressive symptoms in bipolar patients admitted to a psychiatric Unit due…
- Trial name
- MM1 (NCT00690248)
- Where
- 34 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00256113
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 467 people
- Sponsor
- Sanofi
Depression, Postpartum
Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
Type 2 Diabetes (T2DM) is a life-long, chronic condition affecting an individuals' ability to regulate glucose levels in the blood. Diabetes can cause many severe complications if not treated properly.
- Trial name
- NCT01602913
- Testing
- Pravastatin alone, Paroxetine alone, Pravastatin and paroxetine combined
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
Mental Health Care, Mental Health
Mental Health CPR for Cancer Survivors
This is a parallel, two-arm interventional study comparing the Mental Health CPR behavioral intervention to standard community health education.
- Conditions
- Mental Health Care, Mental Health, Depression Anxiety Disorder
- Trial name
- MH-CPR CaS (NCT07219264)
- Testing
- Mental Health CPR, Standard Community Health Education
- Where
- Puerto Rico
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Ponce Medical School Foundation, Inc.
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Depression
Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
The purpose of this study is to determine if Vortioxetine 20 mg/day will lead to changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with executive functioning and memory during cognitive…
- Trial name
- NCT01607125
- Testing
- Vortioxetine (Lu AA21004)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Postpartum Depression
A Study of BRII-297 in Healthy Adult Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects.
- Trial name
- NCT05845840
- Testing
- BRII-297
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Depression
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of Psychiatric Electroencephalogram Registry (PEER) Interactive to inform medication prescription in subjects with a…
- Trial name
- SMART-MD (NCT02988076)
- Testing
- PEER Interactive Report
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- MYnd Analytics
Depression
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram + Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score measured by the Hamilton Scale (HAM-D).
- Trial name
- LABCATTCJUSS (NCT02532660)
- Testing
- Escitalopram 10mg, LABCAT TCJUSS
- Where
- Brazil
- Volunteers
- 111 people
- Sponsor
- Laboratório Catarinense SA
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus Lithium
This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to…
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00206141
- Testing
- Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
- Where
- 76 sites in Canada, Croatia and 14 more
- Volunteers
- 672 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- PHOENIX (NCT00252330)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 476 people
- Sponsor
- Sanofi
Depression
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject
This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese healthy subjects
- Trial name
- NCT03850834
- Testing
- Ammoxetine Hydrochloride Enteric-coated Tablets
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
- Trial name
- NCT05593029
- Testing
- SEP-363856
- Where
- 77 sites in United States, Bulgaria and 5 more
- Volunteers
- 929 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Disorders
Combination Of PAXIL Tablet And Benzodiazepines
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received…
- Trial name
- NCT00259883
- Testing
- paroxetine
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in…
- Trial name
- NCT00531622
- Testing
- saredutant (SR48968), escitalopram
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 643 people
- Sponsor
- Sanofi